ESMO Media Releases

Mature results from the KEYNOTE-045 trial to be presented today at the ESMO 2017 Congress in Madrid (1) have confirmed significantly longer survival in patients with advanced urothelial cancer who receive the checkpoint inhibitor pembrolizumab after initial chemotherapy, compared to an alternative chemotherapy regimen.

Discrepancies between licensing and reimbursement decisions have an impact on patient access to cancer treatment, according to research presented at the ESMO 2017 Congress in Madrid. 

Body fat distribution in the trunk is more important than body weight when it comes to cancer risk in postmenopausal women, according to a study presented at the ESMO 2017 Congress in Madrid.

Combination immunotherapy as second or third line treatment extends overall survival to at least 15 months in patients with pleural malignant mesothelioma, according to late-breaking results from the MAPS2 trial presented today at the ESMO 2017 Congress in Madrid.

The results of the MONARCH 3 trial, presented at the ESMO 2017 Congress in Madrid (1), showed that adding the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to endocrine therapy improved progression-free survival compared to endocrine therapy alone in the total study population.

Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase III RANGE trial presented today at the ESMO 2017 Congress in Madrid

The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a valid tool for grading orphan drugs, according to research presented at the ESMO 2017 Congress in Madrid.

A 14-year randomised trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings are reported today at the ESMO 2017 Congress in Madrid.

Clinical trials are fundamental to the development of new treatments for cancer, yet the annual accrual to cancer clinical trials worldwide is low, estimated at three to five percent.

Durvalumab improves progression-free survival in patients with locally advanced, unresectable stage III lung cancer, according to late-breaking results from the phase III PACIFIC trial presented today at the ESMO 2017 Congress in Madrid (1) and published in the New England Journal of Medicine. 

The preliminary results of a study to be presented at the ESMO 2017 Congress in Madrid (1) show that socio-psychological factors have become more significant for patients today than physical side effects such as nausea and vomiting, which were among the top concerns in similar studies carried out previously

Osimertinib improves progression-free survival by 54% compared to standard first line therapy in patients with EGFR mutated non-small-cell lung cancer (NSCLC), according to late-breaking results from the FLAURA trial presented today at the ESMO 2017 Congress in Madrid.